Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions

Bibliography

• MCNEIL MM, NASH SL, HAJJEH RA et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980— 1997. Clin. Infect. Dis. (2001) 33(5):641–647.
   PubMed Web of Science ®Google Scholar
• PFALLER MA and DIEKEMA DJ: Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. MicrobioL (2002) 40(10):3551–3557.
   PubMed Web of Science ®Google Scholar
• PAPPAS PG, REX JH, SOBEL JD et al.: Guidelines for treatment of candidiasis. Clin. Infect. Dis. (2004) 38(2):161–189.
   PubMed Web of Science ®Google Scholar
• STEVENS DA, KAN VL, JUDSON MA et al.: Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):696–709.
   PubMed Web of Science ®Google Scholar
• SAAG MS, GRAYBILL RJ, LARSEN RA et al.: Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):710–718.
   PubMed Web of Science ®Google Scholar
• WHEAT J, SAROSI G, MCKINSEY D et al.: Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):688–695.
   PubMed Web of Science ®Google Scholar
• BENNETT JE, KAUFFMAN C, WALSH T et al.: Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. Clin. Infect. Dis. (2003) 36\(Suppl. 3):5123–5127.
   Google Scholar
• REX JH, WALSH TJ, NETTLEMAN M et al.: Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin. Infect. Dis. (2001) 33(1):95–106.
   PubMed Web of Science ®Google Scholar
• JOHNSON MD, DODDS ASHLEY ES, KAYE KS, ELY TS, PERFECT JR: Impact of voriconazole on antifungal expenditures at a tertiary care medical center. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2003) M–986.
   Google Scholar
• FORREST G, WEEKES E, STANDIFORD HC: Antimicrobial management program: continual cost savings at a large teaching medical center. Program and Abstracts of the 4Ist Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, USA (2003) 328.
   Google Scholar
• OSTROSKY-ZEICHNER L, MARR KA, REX JH, COHEN SH: Amphotericin B: time for a new 'gold standard'. Clin. Infect. Dis. (2003) 37(3):415–425.
   PubMed Web of Science ®Google Scholar
• DIXON S, MCKEEN E, TABBERER M, PAISLEY S: Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics (2004) 22(7):421–433.
   PubMed Web of Science ®Google Scholar
• ••Excellent review outlining importantelements in pharmacoeconomic analyses of systemic antifungal therapy.
   Google Scholar
• JOLICOEUR LM, JONES-GRIZZLE AJ, BOYER JG: Guidelines for performing a pharmacoeconomic analysis. Am. J. Hosp. Pharm. (1992) 49(716217301741–1747.
   Google Scholar
• •Excellent review of pharmacoeconomic study methods.
   Google Scholar
• SANCHEZ LA: Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature. Am. J. Health Syst. Pharm. (1999) 56(16):1630–1638.
   PubMed Web of Science ®Google Scholar
• SANCHEZ LA: Pharmacoeconomic principles and methods: including pharmacoeconomics into hospital pharmacy practice. Hosp. Pharm. (1994) 29(11):1035–1036, 1039–1040.
   Google Scholar
• SANCHEZ LA: Pharmacoeconomic principles and methods: an introduction for hospital pharmacists. Hosp. Pharm. (1994) 29(8):774, 777-779.
   Google Scholar
• SANCHEZ LA and LEE J: Use and misuse of pharmacoeconomic terms: a definitions primer. Top. Hosp. Pharm. Manage. (1994) 13(4):11–22.
   PubMedGoogle Scholar
• WILSON LS, REYES CM, STOLPMAN M et al.: The direct cost and incidence of systemic fungal infections. Value Health (2002) 5(1):26–34.
   PubMed Web of Science ®Google Scholar
• ••Key paper describing costs of managinginvasive fungal infections.
   Google Scholar
• WINGARD JR, LEATHER HL, WALSH TJ et al.: Pharmacoeconomic analysis comparing caspofungin to liposomal amphotericin B for empirical therapy for persistently febrile neutropenic patients. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC (2004) 0–1619.
   Google Scholar
• ••First pharmacoeconomic analysis ofcaspofungin versus amphotericin B deoxycholate as empiric therapy for neutropaenic fever.
   Google Scholar
• RENTZ AM, HALPERN MT, BOWDEN R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. (1998) 27(4):781–788.
   PubMed Web of Science ®Google Scholar
• WENZEL R, DEL FAVERO A, KIBBLER C et al.: Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J. Antimimb. Chemother. (2005) 55(3):352–361.
   PubMed Web of Science ®Google Scholar
• ••Key study evaluating costs of voriconazoleversus amphotericin B deoxycholate/other licensed antifungal therapy when managing invasive aspergillosis based on data from a randomised trial.
   Google Scholar
• O'CONNELL B, CRAIG JI, MARCUS RE, LUDLAM H: Cost-effective use of liposomal amphotericin B. Clin. Lab. HaematoL (2002) 24(5):317–319.
   PubMedGoogle Scholar
• LEWIS JS, BOUCHER HW, LUBOWSKI TJ et al.: Cost advantage of voriconazole over amphotericin B for primary treatment of invasive aspergillosis. Pharmacotherapy (2005) 25(0:839-846. Key study evaluating costs of voriconazole versus other licensed antifungal therapy when managing invasive aspergillosis based on data from a randomised trial.
   Google Scholar
• DRANITSARIS G, PHILLIPS P, ROTSTEIN C et al.: Economic analysis of fluconazole versus amphotericin B for the treatment of candidemia in non-neutropenic patients. Pharmacoeconomics (1998) 13(5):509–518.
   PubMed Web of Science ®Google Scholar
• ••Important study evaluating costs oftreating invasive candidiasis with fluconazole or amphotericin B deoxycholate, based data from a randomised clinical trial.
   Google Scholar
• DASBACH EJ, DAVIES GM, TEUTSCH SM: Burden of aspergillosis-related hospitalizations in the United States. Clin. Infect. Dis. (2000) 31(6):1524–1528.
   PubMed Web of Science ®Google Scholar
• KUTI JL, KOTAPATI S, WILLIAMS P: Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics (2004) 22(5):301–310.
   PubMed Web of Science ®Google Scholar
• ••An important cost-minimisation analysisof two lipid amphotericin B formulations for treatment of invasive fungal infections in one medical centre.
   Google Scholar
• FINK JM, LONG JK, GOLDMAN MP: Cost-minimization analysis of lipid amphotericin B products. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2003) A–1361.
   Google Scholar
• MILLER LG, HAJJEH RA, EDWARDS JE JR: Estimating the cost of nosocomial candidemia in the United States. Clin. Infect. Dis. (2001) 32(7):1110.
   PubMed Web of Science ®Google Scholar
• MANSLEY EC, SULLIVAN E, WOOD C, BERGER ML: Caspofitngin versus amphotericin B deoxycholate: do the savings generated from reduced rates of impaired renal function offset the differences in drug cost? Program and Abstracts of the 4Ist Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, USA (2003) 165.
   Google Scholar
• REX JH, PAPPAS PG, KARCHMER AW et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect. Dis. (2003) 36(10):1221–1228.
   PubMed Web of Science ®Google Scholar
• HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl. J. Med. (2002) 347(6):408–415.
   PubMed Web of Science ®Google Scholar
• BUXTON MJ, DUBOIS DJ, TURNER RR et al.: Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin B-based therapies. J. Infect. (1991) 23(1):17–31.
   Google Scholar
• TOLLEMAR J, HOCKERSTEDT K, ERICZON BG, JALANKO H, RINGDEN 0: Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation (1995) 59(1):45–50.
   Google Scholar
• SHARPE MD, GHENT C, GRANT D et al.: Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation (2003) 76(0:977–983.
   PubMedGoogle Scholar
• BIANCOFIORE G, BINDI ML, BALDASSARRI R et al: Antifitngal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl. Int. (2002) 15(7):341–347.
   PubMed Web of Science ®Google Scholar
• MEKA VG, HADLEY S, DALY J et al.: Molecular epidemiology of invasive candida infection withing 100 days after orthotopic liver transplantation. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ii, USA (2003) M–2062.
   Google Scholar
• WAKERLY L, CRAIG AM, MALEK M et al.: Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis. J. Hosp. Infect. (1996) 33(1):35–48.
   PubMed Web of Science ®Google Scholar
• SCHAFFNER A, SCHAFFNER M: Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J. Infect. Dis. (1995) 172(4):1035–1041.
   PubMed Web of Science ®Google Scholar
• SCHARFSTEIN JA, PALTIEL AD, FREEDBERG KA: The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. Med. Decis. Making (1997) 17(4):373–381.
   PubMed Web of Science ®Google Scholar
• MANFREDI R, MASTROIANNI A. CORONADO OV, CHIODO F: Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch. Intern. Med. (1997) 157(1):64–69.
   PubMedGoogle Scholar
• POIRIER JM, HARDY S, ISNARD F et al.: Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen. Ther. Drug. Monit. (1997) 19(5):525–529.
   PubMed Web of Science ®Google Scholar
• SKINNER JL, HARRIS C, AARON MF et al.: Cost-benefit analysis of extended antifungal prophylaxis in ventricular assist devices. ASAIO Journal (2000) 46(5):587–589.
   PubMed Web of Science ®Google Scholar
• KRUPOVA Y, NOVOTNY J, SABO A, MATEICKA F, KRCMERY V JR: Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study. Int. J. Antimicrob. Agents (1998) 10(4):313–316.
   PubMed Web of Science ®Google Scholar
• SAJBEN P, MINARIK T, TOMASIK E et al.: Fluconazole plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study. Support Care Cancer (1993) 1(4):214–216.
   PubMed Web of Science ®Google Scholar
• SCHRODER CP, DE VRIES EG, MULDER NH et al.: Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. J. Antimicrob. Chemother. (1999) 43(5):741–3.
   PubMed Web of Science ®Google Scholar
• BOOGAERTS M, TORMANS G, MAES E, VAN DOORSLAER B: Cost-effectiveness analysis of AmBisome versus amphotericin B in the empiric treatment of febrile neutropenia in adults and children. Blood (1996) 88\(Suppl. 1):501a.
   Google Scholar
• CAGNONI PJ, WALSH TJ, PRENDERGAST MM et al.: Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Clin. Oncol (2000) 18(12):2476–2483. Important analysis of costs associated with management of neutropaenic fever with liposomal amphotericin B versus amphotericin B deoxycholate, using data from a large randomised, double-blind trial.
   Google Scholar
• WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl. J. Med. (1999) 340(10):764–771.
   Google Scholar
• WALSH TJ, TEPPLER H, DONOWITZ GR et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl. J. Med. (2004) 351(14):1391–1402.
   PubMed Web of Science ®Google Scholar
• DREW RH, JOHNSON MD, DODDS ASHLEY ES, PERFECT JR: Rational use of antifungals for invasive fungal infections in the institutional setting. Antibiotic optimization: concepts and strategies in clinical practice, 1st edn. Marcel Dekker, New York, N.Y. (2005):577–644.
   Google Scholar
• WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27(3):603–618.
   PubMed Web of Science ®Google Scholar
• BELDEN TL, DREW RH, PERFECT JR: Predicting subsequent infusion-related reactions from responses to initial doses of amphotericin B lipid complex. Program and abstracts of the American College of Clinical Pharmacy 2002 Spring Practice and Research Forum, Savannah, GA, USA (2002).
   Google Scholar
• RODEN MM, NELSON LD, KNUDSEN TA et al.: Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin. Infect. Dis. (2003) 36(10):1213–1220.
   PubMed Web of Science ®Google Scholar
• JOHNSON MD, DREW RH, PERFECT JR: Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy (1998) 18(5):1053–1061.
   PubMed Web of Science ®Google Scholar
• TIMMERS GJ, ZWEEGMAN S, SIMOONS-SMIT AM et al.: Amphotericin B colloidal dispersion (Amphocil) versus fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant. (2000) 25(8):879–884.
   PubMed Web of Science ®Google Scholar
• DERAY G: Amphotericin B nephrotoxicity. Antimicrob. Chemother. (2002) 49\(Suppl. 0:37–41.
   Google Scholar
• BOWDEN R, CHANDRASEKAR P, WHITE MH et al.: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. (2002) 35(4):359–366.
   PubMed Web of Science ®Google Scholar
• JOHNSON PC, WHEAT LJ, CLOUD GA et al.: Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. (2002) 137(2):105–109.
   PubMed Web of Science ®Google Scholar
• LEENDERS AC, DAENEN S, JANSEN RL et al.: Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br. J. Haematol (1998) 103(1):205–212.
   PubMed Web of Science ®Google Scholar
• LEENDERS AC, REISS P, PORTEGIES P et al.: Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS (1997) 11(12):1463–1471.
   PubMed Web of Science ®Google Scholar
• SHARKEY PK, GRAYBILL JR, JOHNSON ES et al.: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1996) 22(2):315–321.
   PubMed Web of Science ®Google Scholar
• MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl. J. Med. (2002) 347(25):2020–2029.
   PubMed Web of Science ®Google Scholar
• VILLANUEVA A. ARATHOON EG, GOTUZZO E et al.: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. (2001) 33(9):1529–1535.
   Google Scholar
• ARATHOON EG, GOTUZZO E, NORIEGA LM et al.: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. (2002) 46(2):451–457.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl. J. Med. (2002) 346(4):225–234.
   PubMed Web of Science ®Google Scholar
• WALSH T, SABLE C, DEPAUW B et al.: A randomized, double-blind, multicenter trial of caspofungin v liposomal amphotericin B for empirical antifungal therapy of persistently febrile neutropenic patients. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA (2003) M–1761.
   Google Scholar
• WALSH TJ, GROLL AH: Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl. Infect. Dis. (1999) 1(4):247–261.
   PubMedGoogle Scholar
• GREENBERG RN, CAGNONI PJ, WINGARD JR, PRENDERGAST MM, TONG KB: Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. J. Med. Econ. (2002)
   Google Scholar
• BATES DW, SU L, YU DT et al.: Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. (2001) 32(5):686–693.
   PubMed Web of Science ®Google Scholar
• HARBARTH S, BURKE JP, LLOYD JF et al.: Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin. Infect. Dis. (2002) 35(12) el 20-el 27.
   Google Scholar
• GRYBET S, CRONIN SM, SOBEL JW, BINDLISH V: Arnphotericin B usage evaluation at a university teaching hospital. ASHP Midyear Clinical Meeting, New Orleans, LA, USA (1991).
   Google Scholar
• NINNO SD, NINNO MA: Optimizing the use of amphotericin B lipid complex. ASHP Midyear Clinical Meeting, New Orleans, LA, USA (1996).
   Google Scholar
• GABARDI S, FIUMARA K, LOWRY C, FANIKOS J: Drug utilization evaluation of liposomal amphotericin B at a large, urban, academic medical center, with a focus on drug dosing over the past six years. ASHP Midyear Clinical Meeting Orlando, FL, USA (2004).
   Google Scholar
• SANDERSON B, JONES TA: Assessment of salt-loading in patients receiving amphotericin B preparatons. ASHP Midyear Clinical Meeting New Orleans, LA, USA (2003).
   Google Scholar
• KENNEDY LD, CONNELLY JF, KUZMA KM: Two-year longitudinal evaluation of amphotericin B lipid complex injection in a tertiary care medical center. Hosp. Pharm. (2001) 36(2):176–191.
   Google Scholar
• CHAN S, FORREST GN, KLEINBERG M, DONNENBERG MS: Significant cost savings with implementation of lipid amphotericin B guidelines at a university cancer center. Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) 0–999.
   Google Scholar
• LOMAESTRO B, ROGLER B: A large teaching hospital's utilization of systemic antifungal therapy. ASHP Midyear Clinical Meeting, New Orleans, LA, USA (2003).
   Google Scholar
• COLLINS CD, PEDERSEN CA, SCHNEIDER PJ et al.: Effect on amphotericin B lipid complex use of a clinical decision support system for computerized prescriber order entry. Am. J. Health Syst. Pharm. (2004) 61(13):1395–1399.
   PubMed Web of Science ®Google Scholar
• GALLAGHER JC, LEE KB: Program to restrict use of iv. fluconazole. Am. J. Health Syst. Pharm. (2004) 61(16):1695–1698.
   PubMed Web of Science ®Google Scholar
• BURKIEWICZ JS, KOSTIUK KA, JACOBS RA, GUGLIELMO BJ: Impact of an intravenous fluconazole restriction policy on patient outcomes. Ann. Pharmacotherapy (2001) 35(1):9–13.
   PubMed Web of Science ®Google Scholar
• ARNOLD T, DONEGAN S, KLEINBERG M, FORREST G: Cost-effectiveness of implementing an IV antifungal to oral voriconazole conversion in a cancer center. Program and Abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, USA (2005) 690.
   Google Scholar
• PHILLIPS P, SHAFRAN S, GARBER G et al.: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur. j Clin. Microbiol Infect. Dis. (1997) 16(5):337–345.
   PubMed Web of Science ®Google Scholar